Results 171 to 180 of about 444,200 (304)
A dataset for assessing phytolith data for implementation of the FAIR data principles. [PDF]
Kerfant C +5 more
europepmc +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Addressing barriers in FAIR data practices for biomedical data. [PDF]
Hughes LD +12 more
europepmc +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
FAIR data gaps and collaboration willingness among hemoglobinopathy research centers. [PDF]
Tamana S +5 more
europepmc +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Making Research Data Published to the Web FAIR [Video] [PDF]
Recording of a presentation discussing the work undertaken by the University of Sheffield’s Library to mitigate potential data loss from research published online.
Hooper, Bryony, Campbell, Ric
core
The missing link in FAIR data policy: biodata resources in life sciences. [PDF]
Poveda L +7 more
europepmc +1 more source
Fair Data Representation for Machine Learning at the Pareto Frontier. [PDF]
Xu S, Strohmer T.
europepmc +1 more source
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source

